Press Releases July 27, 2026 04:05 PM

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

Bionano Genomics schedules Q2 2026 earnings call and webcast for August 10, 2026.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BNGO

Bionano Genomics, Inc. announced it will report its second quarter 2026 financial results on August 10, 2026, and hold a conference call and webcast to discuss recent corporate progress. The event will be accessible via live webcast and replay to investors.

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026
BNGO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Bionano Genomics will report Q2 2026 financial results on August 10, 2026.
  • A conference call and live webcast will be held at 4:30 p.m. ET to discuss results and corporate progress.
  • Replay will be available on the company's investor relations website for 30 days following the call.

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2026 and to highlight recent corporate progress.

Conference Call & Webcast Details

Date:Monday, August 10th, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here


Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionano.com/ for at least 30 days.

CONTACTS

Company Contact:
Al Luderer, Chairman & Interim CEO
Bionano Genomics, Inc.
+1 (781) 507-4438
Aluderer@bionano.com

Investor Relations:
Webb Campbell
Gilmartin Group
+1 (415) 520-5817
IR@bionano.com


Risks

  • Financial results may not meet investor expectations, causing stock volatility.
  • Market reception depends on the progress highlighted during the call, which could affect investor confidence.
  • The biotechnology sector’s inherent risks related to regulatory approvals and technology adoption may impact company performance.

More from Press Releases

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse Sep 20, 2026 Qfin Holdings Announces Changes in Management and Board Composition Sep 20, 2026 Coherent Showcases Optical Innovations to Scale AI Infrastructure at ECOC 2026 Sep 20, 2026 Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Sep 20, 2026 MISSION SUCCESS: Rocket Lab Launches 96th Electron Mission Sep 19, 2026